Due to its highly vascular nature, antiangiogenic tyrosine kinase inhibitors (TKIs) that target the vascular endothelial growth factor (VEGF) pathway have emerged as the most effective treatment for patients with advanced HCC (aHCC) [4]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.